CN114423427A - 治疗具有肾损害的患者的法布里病的方法 - Google Patents

治疗具有肾损害的患者的法布里病的方法 Download PDF

Info

Publication number
CN114423427A
CN114423427A CN202080042938.3A CN202080042938A CN114423427A CN 114423427 A CN114423427 A CN 114423427A CN 202080042938 A CN202080042938 A CN 202080042938A CN 114423427 A CN114423427 A CN 114423427A
Authority
CN
China
Prior art keywords
migalastat
patient
frequency
time period
during
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080042938.3A
Other languages
English (en)
Chinese (zh)
Inventor
富兰克林·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CN114423427A publication Critical patent/CN114423427A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202080042938.3A 2019-06-11 2020-06-11 治疗具有肾损害的患者的法布里病的方法 Pending CN114423427A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859904P 2019-06-11 2019-06-11
US62/859,904 2019-06-11
PCT/US2020/037174 WO2020252129A1 (en) 2019-06-11 2020-06-11 Methods of treating fabry disease in patients having renal impairment

Publications (1)

Publication Number Publication Date
CN114423427A true CN114423427A (zh) 2022-04-29

Family

ID=71950725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042938.3A Pending CN114423427A (zh) 2019-06-11 2020-06-11 治疗具有肾损害的患者的法布里病的方法

Country Status (16)

Country Link
US (1) US20220313670A1 (https=)
EP (1) EP3982962A1 (https=)
JP (2) JP7677910B2 (https=)
KR (1) KR20220019796A (https=)
CN (1) CN114423427A (https=)
AR (1) AR120055A1 (https=)
AU (2) AU2020291002A1 (https=)
BR (1) BR112021024886A2 (https=)
CA (1) CA3141226A1 (https=)
CL (1) CL2021003280A1 (https=)
EA (1) EA202290024A1 (https=)
IL (1) IL288677A (https=)
MX (1) MX2021015352A (https=)
PH (1) PH12021553102A1 (https=)
TW (1) TW202112372A (https=)
WO (1) WO2020252129A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US12594268B2 (en) 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266571A1 (en) * 2007-04-26 2010-10-21 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
CN103974619A (zh) * 2011-03-11 2014-08-06 阿米库斯医疗股份有限公司 治疗法布里病的给药方案
WO2018222655A1 (en) * 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
AU2018220047A1 (en) * 2009-02-12 2018-12-20 Amicus Therapeutics, Inc. A method for treatment of fabry disease
CN109661230A (zh) * 2016-07-19 2019-04-19 阿米库斯治疗学公司 治疗ert初治的和已经历ert的患者中的法布里病
CN110381987A (zh) * 2017-01-05 2019-10-25 波塔力克斯有限公司 使用稳定化α-半乳糖苷酶治疗法布里病的治疗方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
RS65230B1 (sr) * 2017-05-30 2024-03-29 Amicus Therapeutics Inc Migalastat za lečenje pacijenata koji boluju od fabrijeve bolesti sa oštećenjem bubrega

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266571A1 (en) * 2007-04-26 2010-10-21 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
AU2018220047A1 (en) * 2009-02-12 2018-12-20 Amicus Therapeutics, Inc. A method for treatment of fabry disease
CN103974619A (zh) * 2011-03-11 2014-08-06 阿米库斯医疗股份有限公司 治疗法布里病的给药方案
CN107088225A (zh) * 2011-03-11 2017-08-25 阿米库斯治疗学公司 治疗法布里病的给药方案
CN109661230A (zh) * 2016-07-19 2019-04-19 阿米库斯治疗学公司 治疗ert初治的和已经历ert的患者中的法布里病
CN110381987A (zh) * 2017-01-05 2019-10-25 波塔力克斯有限公司 使用稳定化α-半乳糖苷酶治疗法布里病的治疗方法
WO2018222655A1 (en) * 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANKLIN K. JOHNSON: "An Open‐Label Study to Determine the Pharmacokinetics and Safety of Migalastat HCl in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function", CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, vol. 4, no. 4, pages 256 - 261, XP009507828, DOI: 10.1002/cpdd.149 *

Also Published As

Publication number Publication date
AU2026200618A1 (en) 2026-04-16
WO2020252129A1 (en) 2020-12-17
IL288677A (en) 2022-02-01
EP3982962A1 (en) 2022-04-20
PH12021553102A1 (en) 2023-10-09
BR112021024886A2 (pt) 2022-01-25
CL2021003280A1 (es) 2022-10-07
KR20220019796A (ko) 2022-02-17
US20220313670A1 (en) 2022-10-06
CA3141226A1 (en) 2020-12-17
JP2025131572A (ja) 2025-09-09
AR120055A1 (es) 2022-02-02
AU2020291002A1 (en) 2022-01-06
MX2021015352A (es) 2022-04-06
JP7677910B2 (ja) 2025-05-15
TW202112372A (zh) 2021-04-01
EA202290024A1 (ru) 2022-03-14
JP2022536687A (ja) 2022-08-18

Similar Documents

Publication Publication Date Title
KR102631805B1 (ko) 신장 손상을 갖는 파브리 환자를 치료하는 방법
CN114423427A (zh) 治疗具有肾损害的患者的法布里病的方法
AU2025217396A1 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
JP7784398B2 (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
KR102790184B1 (ko) 파브리병을 앓는 환자에서 심장 기능을 강화 및/또는 안정화시키는 방법
KR102004114B1 (ko) Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
AU2025200074A1 (en) Treatment of patients with classic fabry disease
CN111971044A (zh) 米加司他用于治疗妊娠患者的法布里病的用途
JP2026016375A (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2025128105A (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
CN111278438A (zh) 治疗具有肾损害的法布里患者的方法
HK40073744A (en) Methods of treating fabry disease in patients having renal impairment
HK40085360A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40039916A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
HK40044440A (en) Treatment of patients with classic fabry disease
HK40031708A (en) Methods of treating fabry patients having renal impairment
HK40044013A (en) Use of migalastat for treating fabry disease in pregnant patients
HK40001720A (en) Methods of treating fabry disease in patients having the g9331a mutation in the gla gene

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073744

Country of ref document: HK